CALI, a wearable physical therapy device for those with vertigo, pitched at the annual event. Photo via getcalibalance.com

These are the 16 Houston startups coming out of UH's RED Labs and Rice's OwlSpark

Best in class

For the sixth year, the University of Houston and Rice University have joined forces to give their student entrepreneurs a program to thrive in. RED Labs and OwlSpark, the two universities' accelerator programs, just concluded their seventh class with a presentation from the companies.

Over the past 12 weeks, these 16 startups and their teams of entrepreneurs have worked on their company, developing it, learning how to fundraise for it, and engaging with all sorts of other valuable resources and mentors through the program.

"With an emphasis on experimentation and rapid iteration, we teach disciplined startup strategies that help (students) have an eye for reducing risks and increasing odds," says Kerri Smith, managing director of OwlSpark.

This summer's cohort was hosted out of Station Houston this year, but the two universities have worked together since year two of each of their programs.

"We're very proud of our partnership, because in most other cities, two universities like this would probably be rivals, but we're interested in camaraderie and collaboration in this cohort because they are the future generation of entrepreneurs of Houston," says Kelly McCormick, director of RED Labs. "We really think that this sets an example of how working together produces better results than working against each other."

Adren

While the invention of the EpiPen and other compact anaphylaxis solutions have saved lives, the products are still too large to be constantly available to those who need it. Adren's co-founders created a collapsible autoinjector that can be work as a wristband.

"A functioning drug is only one piece of the puzzle," says Jacob, co-founder of Adren. (He didn't state his last name.) "Medication is only effective if it is accessible to the patient."

The company plans to continue on and patent their product with hopes to enter the marketplace by the next few years.

CookLab

Anyone can find a recipe for anything with the tap of a few keys and the click of of few buttons, but once you add in dietary restrictions, things get tricky. Not to mention the fact that so many healthy recipes aren't even that good for you.

The team at CookLab wants to eliminate this unregulated and confusing corner of the internet. CookLab's first product is a web tool that can determine whether or not a recipe is healthy by the user dropping in the URL. This product is in beta right now.

Down the road, CookLab wants to create a tool for users to be able to submit a recipe they want to make, then have CookLab generate a modified version that follows any dietary needs.

INSU

In a state of emergency where electricity is out, the diabetic population is forced to gamble with their lives when it comes to keeping their insulin insulated and cool.

INSU has a solution. The startup has created a battery operated cooler that can keep insulin from spoiling for 30 days. The battery can be charged by wall outlet or even solar panel.

The company plans to market directly to consumers as well as make strategic partnerships with emergency and health organizations.

auggie

Merchandise lines at concerts are quite possibly the single-most buzzkill of any show. In the age of UberEats and order-ahead apps, auggie sees a solution.

While you're at a show, you can easily order your favorite merch items on the app and choose to have it set aside for pickup that day or even get it mailed to you. The app is live on some downloading stores.

LilySpec

The speculum OB/GYNs use on their patients hasn't changed in 150 years, and, while effective, can be uncomfortable to patients during use. But this doesn't have to be the case.

LilySpec is a speculum designed with the patient in mind. The device is silently deployed, silicon coated for comfort, and adjustable for all women.

The LilySpec team will finish its clinical product this year, and the company's medical partners here in Texas will be able to use it on patients.

Myze

How do you staff a team for an unpredictable job? Emergency rooms face this challenge every single shift. Too many staffers makes the establishment bleed money, while too few causes burnout and even sacrifices quality of care.

Myze is developing a software platform that can use artificial intelligence and predictive analytics to help ERs better staff their teams.

CALI

Those suffering from Vertigo feel like the whole world has turned upside down. CALI is a device that helps those people turn it right back around.

The wearable device allows for users to do balance exercises and claim back control of their own situation.

DASH Innovations

For those relying on a catheter, changing it out requires 150 monthly procedures on average. Each one is another opportunity for infection.

DASH Innovations has created UrinControl, a urethral valve for pediatric patients that can be installed once a month and operated with a remote to control the bladder.

Get-A-Grip

Holding onto a cup is something most everyone takes for granted. For arthritis or muscle damage patients, it's a daunting daily task.

Get-A-Grip is designed to distribute the weight of the cup along the grip and make it easier and more comfortable to hold. While originally designed with these patients in mind, the grip comes in four sizes, with the smallest being perfect for babies grabbing at bottles or small children holding cups.

Everest Security

Preparing for and preventing phishing email-originated data breaches is the new normal for companies, but it's impossible to prevent employees from accidentally opening suspicious emails without thinking.

While there are plenty software protection companies out there, Everest Security couples their software solution with education, a core component for the company.

KickedOC

There are 2 million homes supposedly dedicated for off-campus housing for students, but no one-stop shop to find them. KickedOC is attempting to be that one-stop shop and make it easier for students to find their semester homes.

With listings already up in Houston, the startup hopes to expand its platform to College Station and other Texas college towns next.

Mismo Minds

Creating a creative team can be difficult if you don't have the connections already. Mismo Minds is a platform for artists, videographers, directors, etc. to join forces with others who share their creative vision. It's a social networking tool, project management platform, and job board all rolled into one.

Sports Betz

Typically for sports betting, you have two options: Impersonal bets with large pools or friendly wagers that might not ever pay off. Sports Betz is a platform where the competitive gamblers can casually bet with friends and family — but the money is pulled up front.

CIND

Chivalry is not dead, argues CIND, a new dating app. The app allows for potential matches to introduce themselves with a gift — which range from $2 to $100. Though, the recipient doesn't just walk away with the cash. The money actually goes to the recipient's nonprofit of choice. Only after the donation is made can matches start chatting.

CIND (pronounced like "Cindy") is basically digital donation dating, and everyone wins.

PCATCopycat

The Pharmacy College Admission Test isn't easy — and preparation isn't cheap.

PCATCopycat puts the power back into the hands of students. The online course is only $200 — way cheaper and easier for future pharmacists to navigate.

Second Act

Second Act is the startup that isn't. The non-company started the program with the idea of matching retirees with short-term work at various startups with the thought being that they have a lot of experience and a lot of time on their hands. While a great idea in theory, Second Act hit some walls and the company and idea are no more. The team, however, has a bright future in Houston innovation at other startups and companies.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.